Cover Image
市場調查報告書

Pfizer Inc.的產品平台分析

Pfizer Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 253699
出版日期 內容資訊 英文 419 Pages
訂單完成後即時交付
價格
Back to Top
Pfizer Inc.的產品平台分析 Pfizer Inc. - Product Pipeline Review - 2016
出版日期: 2016年03月16日 內容資訊: 英文 419 Pages
簡介

Pfizer Inc.是總公司設在美國的製藥企業,是以研究為基本的全球性製藥企業。進行藥物、疫苗、一般用醫藥品等藥物研發、開發、製造、行銷,對象領域包括呼吸疾病、心血管系統疾病、代謝系疾病、感染疾病、發炎、腫瘤、眼科系疾病、神經科學、疼痛、組織修復、腸胃疾病、婦產科系疾病、罕見疾病、泌尿器官系統疾病等多方面。

本報告提供Pfizer Inc. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Pfizer Inc. 的基本資料

  • Pfizer Inc. 概要
  • 主要資訊
  • 企業資料

Pfizer Inc. :R&D概要

  • 主要的治療範圍

Pfizer Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
  • 轉出授權產品

Pfizer Inc. :開發中產品概況

  • 後期階段的開發中產品
  • 臨床階段的開發中產品
  • 初期階段的開發中產品

Pfizer Inc.:藥物簡介

  • (oxycodone hydrochloride + naltrexone) ER
  • (piperacillin sodium + tazobactam sodium)
  • bazedoxifene acetate
  • crizotinib
  • tofacitinib
  • tafamidis meglumine
  • adalimumab biosimilar
  • axitinib
  • bevacizumab biosimilar
  • bococizumab
  • bosutinib
  • dacomitinib
  • diazepam
  • ertugliflozin
  • gosogliptin
  • infliximab biosimilar
  • inotuzumab ozogamicin
  • meningococcal meningitis serotype B vaccine
  • palbociclib
  • pregabalin
  • pregabalin CR
  • rituximab biosimilar
  • rivipansel sodium
  • sildenafil citrate
  • sunitinib malate
  • trastuzumab biosimilar
  • agatolimod sodium
  • ascrinvacumab
  • Dekavil
  • fosdagrocorat
  • glasdegib
  • MultiStem
  • PF-00489791
  • PF-00547659
  • PF-02545920
  • PF-03084014
  • PF-03715455
  • PF-04236921
  • PF-04457845
  • PF-04634817
  • PF-04937319
  • PF-04965842
  • PF-05089771
  • PF-05175157
  • PF-05212377
  • PF-06252616
  • PF-06290510
  • PF-06291874
  • PF-06372865
  • PF-06425090
  • PF-06473871
  • ponezumab
  • tanezumab
  • temsirolimus
  • ziprasidone hydrochloride
  • gedatolisib
  • PF-06463922
  • PF-06747775
  • celecoxib
  • HIV vaccine
  • KUX-1151
  • PD-0325901 + PF-05212384
  • PF-04518600
  • PF-04958242
  • PF-05082566
  • PF-05206388
  • PF-05230907
  • PF-05280602
  • PF-05402536
  • PF-06260414
  • PF-06263276
  • PF-06263507
  • PF-06273340
  • PF-06282999
  • PF-06293620
  • PF-06342674
  • PF-06409577
  • PF-06412562
  • PF-06413367
  • PF-06427878
  • PF-06444752
  • PF-06444753
  • PF-06480605
  • PF-06647020
  • PF-06647263
  • PF-06648671
  • PF-06649751
  • PF-06650808
  • PF-06650833
  • PF-06651600
  • PF-06664178
  • PF-06669571
  • PF-06678552
  • PF-06687859
  • PF-06700841
  • PF-4447943
  • Antibody to Antagonize IL-7 Receptor for Type 1 Diabetes
  • Biologics for Undisclosed Indication
  • Biologics to Target PCSK-9 for Undisclosed Indication
  • CE-355621
  • Drugs for Duchenne Muscular Dystrophy
  • GIBH-1008
  • GIBH-1010
  • GIBH-1018
  • GL-2045
  • HSD-621
  • Monoclonal Antibodies for Solid Tumor
  • NIC7-DT
  • NOX-B11
  • PF-06380101
  • PF-06447475
  • PF-2988403
  • PF-3306138
  • PF-3826719
  • PF-3845
  • PF-4942847
  • PF-4989216
  • PF-5006739
  • PNU-120596
  • Proteins to Agonize MC4R for Obesity
  • RBT-301
  • Small Molecule for Neurological Disorders
  • Small Molecule to Antagonize Tie-2 Receptor for Solid Tumor
  • Small Molecule to Inhibit HPGDS for Asthma
  • Small Molecule to Inhibit IDO1 for Cancer
  • Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections
  • Small Molecule to Inhibit TDO-2 for Cancer
  • Small Molecule to Modulate Androgen Receptor for Muscle Disorders
  • Small Molecules to Activate CFTR for Cystic Fibrosis
  • Small Molecules to Inhibit NMT for Malaria
  • Small Molecules to Inhibit PDE2 for Osteoarthritis Pain
  • Vaccine 2 for Undisclosed Indication
  • Antisense Oligonucleotide for Undisclosed Indication
  • Drug to Agonize Melanocortin Receptor 3 for Rheumatoid Arthritis and Inflammation
  • Monoclonal Antibody Conjugate for Cancer
  • Monoclonal Antibody Conjugates for Oncology
  • PF-00190434
  • PF-04445597
  • PF-2311200
  • PF-2345185
  • PF-2614170
  • PF-3604861
  • PF-3686093
  • PF-46396
  • PPD-1
  • Small Molecule to Agonize LXR for Inflammation
  • Small Molecule to Antagonize Ghrelin for Alcoholism
  • Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease
  • Small Molecule to Inhibit NS5A for HCV
  • Small Molecule to Inhibit PI3K and mTOR for Cancer
  • Small Molecule to Inhibit Pin1 for Cancer
  • Small Molecule to Target AGTR1 and PPAR gamma for Hypertension and Metabolic Syndrome
  • Small Molecules for Inflammatory and Orphan Diseases
  • Small Molecules for Obesity and Diabetes
  • Small Molecules for Ulcerative Colitis and Crohn's Disease
  • Small Molecules to Agonize A1 Adenosine Receptor for Undisclosed Indication

Pfizer Inc. :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Pfizer Inc. :最新的開發平台資訊

Pfizer Inc. :開發暫停中的計劃

Pfizer Inc. :開發中止的開發中產品

  • 開發中止的開發中產品簡介

Pfizer Inc. :企業理念

Pfizer Inc. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07989CDB

Summary

Global Markets Direct's, 'Pfizer Inc. - Product Pipeline Review - 2016', provides an overview of the Pfizer Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Pfizer Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Pfizer Inc.
  • The report provides overview of Pfizer Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Pfizer Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Pfizer Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Pfizer Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pfizer Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pfizer Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Pfizer Inc. Snapshot
  • Pfizer Inc. Overview
  • Key Information
  • Key Facts
  • Pfizer Inc. - Research and Development Overview
  • Key Therapeutic Areas
  • Pfizer Inc. - Pipeline Review
  • Pipeline Products by Stage of Development
  • Pipeline Products - Monotherapy
  • Pipeline Products - Combination Treatment Modalities
  • Pipeline Products - Partnered Products
  • Pipeline Products - Out-Licensed Products
  • Pfizer Inc. - Pipeline Products Glance
  • Pfizer Inc. - Late Stage Pipeline Products
  • Pfizer Inc. - Clinical Stage Pipeline Products
  • Pfizer Inc. - Early Stage Pipeline Products
  • Pfizer Inc. - Drug Profiles
  • (naltrexone hydrochloride + oxycodone hydrochloride) ER
  • crizotinib
  • palbociclib
  • tofacitinib
  • epoetin zeta
  • gemtuzumab ozogamicin
  • tafamidis meglumine
  • (ertugliflozin + metformin hydrochloride)
  • (ertugliflozin + sitagliptin phosphate)
  • adalimumab biosimilar
  • axitinib
  • bevacizumab biosimilar
  • bococizumab
  • bosutinib
  • celecoxib
  • dacomitinib
  • ertugliflozin
  • gosogliptin
  • infliximab biosimilar
  • inotuzumab ozogamicin
  • meningococcal [serotype B] vaccine
  • pregabalin
  • pregabalin CR
  • rituximab biosimilar
  • rivipansel sodium
  • sildenafil citrate
  • sunitinib malate
  • tanezumab
  • trastuzumab biosimilar
  • ziprasidone mesylate
  • ascrinvacumab
  • Dekavil
  • domagrozumab
  • fosdagrocorat
  • gedatolisib
  • glasdegib
  • lorlatinib
  • Nimenrix
  • nirogacestat
  • PF-00489791
  • PF-00547659
  • PF-02545920
  • PF-04236921
  • PF-04457845
  • PF-05089771
  • PF-06290510
  • PF-06291874
  • PF-06425090
  • PF-06838435
  • ponezumab
  • temsirolimus
  • agatolimod sodium
  • pegfilgrastim
  • PF-06747775
  • filgrastim
  • HIV vaccine
  • PF-04136309
  • PF-04447943
  • PF-04518600
  • PF-04958242
  • PF-05082566
  • PF-05206388
  • PF-05230907
  • PF-05251749
  • PF-05402536
  • PF-06266047
  • PF-06273340
  • PF-06282999
  • PF-06293620
  • PF-06342674
  • PF-06412562
  • PF-06413367
  • PF-06427878
  • PF-06444752
  • PF-06444753
  • PF-06480605
  • PF-06647020
  • PF-06647263
  • PF-06648671
  • PF-06649751
  • PF-06650808
  • PF-06650833
  • PF-06651600
  • PF-06664178
  • PF-06669571
  • PF-06678552
  • PF-06700841
  • PF-06741086
  • PF-06751979
  • PF-06753512
  • PF-06755990
  • PF-06755992
  • PF-06801591
  • PF-06815345
  • Biologics for Undisclosed Indication
  • Biologics to Target PCSK-9 for Hypercholesterolemia
  • CE-355621
  • Drugs for Duchenne Muscular Dystrophy
  • GIBH-1008
  • GIBH-1010
  • GIBH-1018
  • GL-2045
  • HSD-621
  • J-17
  • Monoclonal Antibodies for Solid Tumor
  • MOR-8457
  • NIC7-DT
  • PD-0360324
  • PF-01247324
  • PF-06380101
  • PF-06447475
  • PF-06671008
  • PF-1355
  • PF-3845
  • PF-4989216
  • PF-5006739
  • PNU-120596
  • Proteins to Agonize MC4R for Obesity
  • RBT-301
  • Small Molecule 1 for Solid Tumors
  • Small Molecule to Antagonize Tie-2 Receptor for Solid Tumor
  • Small Molecule to Inhibit IDO-1 for Oncology
  • Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections
  • Small Molecule to Inhibit TDO-2 for Oncology
  • Small Molecule to Modulate Androgen Receptor for Muscle Disorders
  • Small Molecules to Activate CFTR for Cystic Fibrosis
  • Small Molecules to Inhibit Mps1 for Breast Cancer
  • Small Molecules to Inhibit NMT for Malaria
  • Small Molecules to Inhibit PDE2 for Osteoarthritis Pain
  • Vaccine 2 for Undisclosed Indication
  • Monoclonal Antibody Conjugates for Oncology
  • PF-00190434
  • PF-04445597
  • PF-46396
  • PPD-1
  • Small Molecule to Agonize LXR for Inflammation
  • Small Molecule to Agonize Melanocortin Receptor 3 for Rheumatoid Arthritis and Inflammation
  • Small Molecule to Antagonize Ghrelin Receptor for Alcoholism
  • Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease and Congenital Adrenal Hyperplasia
  • Small Molecule to Inhibit Acetyl-CoA Carboxylase for Metabolic Disorders
  • Small Molecule to Inhibit EZH2 for Oncology
  • Small Molecule to Inhibit MMP13 for Osteoarthritis
  • Small Molecule to Inhibit NS5A for HCV
  • Small Molecule to Inhibit PI3K Alpha and mTOR for Oncology
  • Small Molecule to Inhibit Pin1 for Oncology
  • Small Molecule to Target AGTR1 and PPAR gamma for Hypertension and Metabolic Syndrome
  • Small Molecules for Inflammatory and Orphan Diseases
  • Small Molecules for Obesity and Diabetes
  • Small Molecules for Ulcerative Colitis and Crohn's Disease
  • Small Molecules to Agonize A1 Adenosine Receptor
  • Small Molecules to Agonize ADRB2 and Antagonize CHRM3 for COPD
  • Pfizer Inc. - Pipeline Analysis
  • Pfizer Inc. - Pipeline Products by Target
  • Pfizer Inc. - Pipeline Products by Route of Administration
  • Pfizer Inc. - Pipeline Products by Molecule Type
  • Pfizer Inc. - Pipeline Products by Mechanism of Action
  • Pfizer Inc. - Recent Pipeline Updates
  • Pfizer Inc. - Dormant Projects
  • Pfizer Inc. - Discontinued Pipeline Products
  • Discontinued Pipeline Product Profiles
  • Pfizer Inc. - Company Statement
  • Pfizer Inc. - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Pfizer Inc., Key Information
  • Pfizer Inc., Key Facts
  • Pfizer Inc. - Pipeline by Indication, 2016
  • Pfizer Inc. - Pipeline by Stage of Development, 2016
  • Pfizer Inc. - Monotherapy Products in Pipeline, 2016
  • Pfizer Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Pfizer Inc. - Partnered Products in Pipeline, 2016
  • Pfizer Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Pfizer Inc. - Out-Licensed Products in Pipeline, 2016
  • Pfizer Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Pfizer Inc. - Pre-Registration, 2016
  • Pfizer Inc. - Filing rejected/Withdrawn, 2016
  • Pfizer Inc. - Phase III, 2016
  • Pfizer Inc. - Phase II, 2016
  • Pfizer Inc. - Phase I, 2016
  • Pfizer Inc. - Preclinical, 2016
  • Pfizer Inc. - Discovery, 2016
  • Pfizer Inc. - Pipeline by Target, 2016
  • Pfizer Inc. - Pipeline by Route of Administration, 2016
  • Pfizer Inc. - Pipeline by Molecule Type, 2016
  • Pfizer Inc. - Pipeline Products by Mechanism of Action, 2016
  • Pfizer Inc. - Recent Pipeline Updates, 2016
  • Pfizer Inc. - Dormant Developmental Projects,2016
  • Pfizer Inc. - Discontinued Pipeline Products, 2016
  • Pfizer Inc., Other Locations
  • Pfizer Inc., Subsidiaries

List of Figures

  • Pfizer Inc. - Pipeline by Top 10 Indication, 2016
  • Pfizer Inc. - Pipeline by Stage of Development, 2016
  • Pfizer Inc. - Monotherapy Products in Pipeline, 2016
  • Pfizer Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Pfizer Inc. - Partnered Products in Pipeline, 2016
  • Pfizer Inc. - Out-Licensed Products in Pipeline, 2016
  • Pfizer Inc. - Pipeline by Top 10 Target, 2016
  • Pfizer Inc. - Pipeline by Route of Administration, 2016
  • Pfizer Inc. - Pipeline by Top 10 Molecule Type, 2016
  • Pfizer Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top